TerSera Therapeutics LLC's Infusion Specialty Therapies Business Unit
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
TerSera Therapeutics LLC's Infusion Specialty Therapies Business Unit - overview
Location
-, -, US
Primary Industry
Biotechnology
About
Based in the US, TerSera Therapeutics LLC's Infusion specialty therapies business unit specializes in developing innovative biopharmaceuticals aimed at addressing unmet medical needs through targeted therapies and comprehensive support services. In January 2026, Esteve Healthcare, S. L. , a portfolio company of Lubea, agreed to acquire TerSera Therapeutics LLC's Infusion specialty therapies business unit from TerSera Therapeutics LLC and GTCR.
The transaction is subject to regulatory approvals and is expected to be completed in the first quarter of 2026. The IST business unit comprises two specialty therapies supported by comprehensive medical, commercial, and operational infrastructure. Prialt (ziconotide intrathecal infusion) is a non-opioid analgesic delivered via intrathecal pump for adults with severe chronic pain who are intolerant or refractory to systemic analgesics, adjunctive therapies, or intrathecal morphine. As the only FDA approved agent of its kind, Prialt provides a critical treatment option within complex pain management pathways.
Quzyttir (cetirizine hydrochloride injection) is an IV formulation indicated for acute urticaria in adults and children as young as six months old, offering physicians a second generation, non-sedating antihistamine alternative to older injectable therapies.
Current Investors
Esteve Healthcare, S.L.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Specialty Pharmaceuticals
Verticals
HealthTech
Total Amount Raised
Subscriber access only
TerSera Therapeutics LLC's Infusion Specialty Therapies Business Unit - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Corporate Carve Out, LP Direct | Completed | TerSera Therapeutics LLC's Infusion Specialty Therapies Business Unit | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.